Paratek Announces Expansion of NUZYRA Launch into the Community Setting - Seite 2

To support the launch of NUZRYA into the community setting, Paratek has initiated the hiring of approximately 40 U.S. community-based sales representatives, which will complement its established and successful hospital-based sales organization. Upon completion of the current community-based expansion, Paratek anticipates having a sales force to address both the community and hospital settings of approximately 90-100 customer facing representatives. The Company expects to execute this expansion within its previously communicated cash runway guidance. The expansion of the sales organization builds upon a focused and targeted community sales pilot program conducted in the second half of 2020. The data provided by the pilot suggest NUZYRA has an opportunity to address significant unmet needs in the community setting through building awareness among primary care physicians, leading to meaningful trial and adoption with positive patient outcomes. Paratek expects to accomplish this initial phase of the community expansion within the first quarter of 2021.

“Every other sector of the pharmaceutical armamentarium has added new, more effective and better tolerated treatment options over the past 20 years while the community antibiotic segment has gone in the other direction, where our choice of treatments has become ever more limited because of a lack of innovation and overwhelming resistance. This shift significantly increases risks to patients,” said Dr. Susan Butler-Sumner, a family medicine physician practicing in the community setting for more than 40 years. “Universally, community-based clinicians in the U.S. are looking for new antibiotic treatment options, particularly safe, well-tolerated and effective once-daily oral options with an accompanying IV formulation if needed. I believe NUZYRA will be able to significantly help address this clinically important treatment gap.”

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use.

The Company’s lead commercial product, NUZYRA (omadacycline), is a once-daily oral and intravenous antibiotic available in the U.S. for the treatment of adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections. Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.